Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, has announced new board appointments. The company named Khoso Baluch and James Neal to its board of directors and appointed current board member Justin Yorke as board chair. According to the announcement, the new appointments are designed to position the company for anticipated milestone while ensuring adherence to high governance standards. Yorke is taking on the role of chair as the company focuses on three ongoing clinical trials and the development of all five of its pipeline products. Baluch has more than three decades of experience across global geographies in the biopharmaceutical industry. Most recently, he has served as an independent director of Poxel SA, a French publicly traded biotech company; he has also served as the board chair for Da Volterra, a French privately held company, and as CEO and board member at CorMedix Inc., a publicly traded U.S. pharmaceutical company in the United States. Neal has garnered more than two decades years of experience in forming and maximizing business and technology collaborations globally and in bringing novel products and technologies to market. Most recently, he has served as CEO and board chair of XOMA Corp. “I’m pleased to welcome both Khoso and Jim to our team,” said Processa Pharmaceuticals CEO Dr. David Young in the press release. “Their comprehensive backgrounds and experience in the biotech space, including licensing and commercialization, make them ideally suited to assist Processa at this stage of its evolution. I look forward to working with them and the rest of our board as we progress towards unlocking numerous value catalysts in our pipeline.”
To view the full press release, visit https://ibn.fm/sEfT7
About Processa Pharmaceuticals Inc.
The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and/or quality of life. The company uses these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently. Active clinical pipeline programs include PCS6422 (“PCS6422”), a metastatic colorectal cancer and breast cancer program; PCS499 (“PCS499”), an ulcerative necrobiosis lipoidica program; and PCS12852 (“PCS12852”), a GI mobility and gastroparesis program. The members of the Processa development team have been involved with more than 30 drug approvals by the FDA, including drug products targeted to orphan disease conditions, and more than 100 FDA meetings throughout their careers. For more information, visit the company’s website at www.ProcessaPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at https://ibn.fm/PCSA
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.